Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.1.02276
European Journal of Endocrinology, Vol 155, Issue 5, 751-756
Copyright © 2006 by Society of the European Journal of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yazdanpanah, M.
Right arrow Articles by van Duijn, C. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yazdanpanah, M.
Right arrow Articles by van Duijn, C. M
CLINICAL STUDY

IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes

Mojgan Yazdanpanah1, Fakhredin A Sayed-Tabatabaei1, Joop A M J L Janssen2, Ingrid Rietveld1,2, Albert Hofman1, Theo Stijnen1, Huibert A P Pols1,2, Steven W J Lamberts2, Jacqueline C M Witteman1 and Cornelia M van Duijn1

1 Departments of Epidemiology and Biostatistics and 2 Internal Medicine, Erasmus Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands

(Correspondence should be addressed to C M van Duijn; Email: c.vanduijn{at}erasmusmc.nl)

Objective: Previously we observed that non-carriers of the most common alleles of an IGF-I promoter polymorphism have low circulating IGF-I levels and an increased risk of developing myocardial infarction (MI), particularly in patients with type 2 diabetes.

Design: We investigated whether this IGF-I promoter polymorphism is associated with survival of type 2 diabetes in a Caucasian population aged 55 years and older.

Methods: The study was embedded in the Rotterdam Study, a prospective population-based cohort study. At baseline, 668 patients with type 2 diabetes were diagnosed, among which, 55 incident MI were ascertained during follow-up. For the present study, we used two genotype groups: non-variant carriers (homozygous for 192, 194, or 192/194 bp genotypes), and variant carriers.

Results: During a median follow-up of 8.8 years, 396 out of the 668 patients with type 2 diabetes (59.3%) died of various causes. The frequency of type 2 diabetes variant carrier and non-variant carriers was 28.7 and 71.3% respectively. The survival in patients with type 2 diabetes without an MI did not differ between the IGF-I genotype groups (hazard ratio (HR) = 0.8, 95% confidence interval (CI): 0.7–1.1, P = 0.1). In contrast, in those who developed an MI, variant carriers had a 2.4 times higher risk of mortality than non-variant carriers (95% CI: 1.2–4.8, P = 0.01).

Conclusion: Our study suggests that genetically determined low IGF-I activity is an important determinant of survival in patients with type 2 diabetes who developed an MI. The IGF-I promoter polymorphism, therefore, may help to predict the future mortality risk in this group of patients.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society of the European Journal of Endocrinology.